Samsung Biologics Co Ltd
- 거래소
- 한국
- 국가 / 지역
- Korea
- 직원 수
- 5,195
종합 밸류에이션 구간 · 보수적 850,000–1,100,000 / 적정 1,250,000–1,600,000 / 낙관적 1,900,000–2,300,000. 1,430,000 기준, 적정 내재가치 구간 내.
보고서 발행 시 1,336,000（2026년 6월 5일）
이 종목에 대한 리포트가 아직 해당 언어로 없습니다.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.
연혁
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.
업계 내 위치
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.